Seqirus announces £40m UK fill-and-finish flu vaccine facility

04:48 EST 9 Nov 2017 | Pharmafile

Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new fill-and-finish facility at its manufacturing site in Liverpool, UK – a move which the company says will create 88 new high-tech jobs, bringing total staff levels at the site to more than 700.

Image caption: 
Pictured, left to right: Dr Laura O’Brien, Vice President of Operations and Site Head at Liverpool, Gordon Naylor, President of Seqirus, Greg Clark, Secretary of State for Business, Maria Eagle, MP for Garston and Halewood, Steve Rotherham, Mayor of the Liverpool City Region

read more

Original Article: Seqirus announces £40m UK fill-and-finish flu vaccine facility


More From BioPortfolio on "Seqirus announces £40m UK fill-and-finish flu vaccine facility"

Quick Search


Relevant Topics

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...